OTCMKTS:NEVPFNeuroVive Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NeuroVive Pharmaceutical AB Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.15 +0.04 (+36.36 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range$0.11Now: $0.15▼$0.1550-Day Range$0.07MA: $0.10▼$0.1252-Week Range$0.06Now: $0.15▼$0.31Volume41,150 shsAverage Volume29,220 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABeta1.4 ProfileAdvanced ChartCompetitorsEarningsHeadlinesSocial Media NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases. The company also develops NVP015/NV354 drug candidates for mitochondrial diseases; NVP025 drug candidate for mitochondrial myopathies; NV556 and NVP022 drug candidates for non-alcoholic steatohepatitis conditions; and NVP024, a hepatocellular carcinoma program. NeuroVive Pharmaceutical AB (publ) has collaboration agreements with Isomerase Therapeutics, Sihuan Pharmaceutical, and Sanofi Korea. The company also has a preclinical collaboration agreement with the Children's Hospital of Philadelphia for research in genetic mitochondrial disorders. NeuroVive Pharmaceutical AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for NeuroVive Pharmaceutical. Previous Next 2.5 Community Rank Outperform VotesNeuroVive Pharmaceutical has received 70 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeuroVive Pharmaceutical has received 70 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeuroVive Pharmaceutical has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about NeuroVive Pharmaceutical and other stocks. Vote “Outperform” if you believe NEVPF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NEVPF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeuroVive Pharmaceutical does not currently pay a dividend.Dividend GrowthNeuroVive Pharmaceutical does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuroVive Pharmaceutical insiders have not sold or bought any company stock. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NeuroVive Pharmaceutical are expected to grow in the coming year, from ($0.04) to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroVive Pharmaceutical is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroVive Pharmaceutical is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroVive Pharmaceutical has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.75 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:NEVPF Previous Symbol CUSIPN/A CIKN/A Webwww.neurovive.com Phone46-4-627-562-20Debt Debt-to-Equity RatioN/A Current Ratio5.51 Quick Ratio5.51Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book0.71Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-7,870,000.00 Net MarginsN/A Return on Equity-42.37% Return on Assets-38.20%Miscellaneous Employees7 Outstanding SharesN/AMarket CapN/A Next Earnings Date6/2/2020 (Estimated) OptionableNot Optionable OTC:NEVPF Rates by TradingView Receive NEVPF News and Ratings via Email Sign-up to receive the latest news and ratings for NEVPF and its competitors with MarketBeat's FREE daily newsletter. NeuroVive Pharmaceutical (OTCMKTS:NEVPF) Frequently Asked Questions How has NeuroVive Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)? NeuroVive Pharmaceutical's stock was trading at $0.0796 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NEVPF stock has increased by 88.4% and is now trading at $0.15. View which stocks have been most impacted by Coronavirus. When is NeuroVive Pharmaceutical's next earnings date? NeuroVive Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, June 2nd 2020. View our earnings forecast for NeuroVive Pharmaceutical. Has NeuroVive Pharmaceutical been receiving favorable news coverage? News stories about NEVPF stock have been trending very positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NeuroVive Pharmaceutical earned a coverage optimism score of 3.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutNeuroVive Pharmaceutical. Who are some of NeuroVive Pharmaceutical's key competitors? Some companies that are related to NeuroVive Pharmaceutical include Addex Therapeutics (ADDXF), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM), Helix Biopharma (HBPCF), MOTIF BIO PLC/S (MTFB), Myrexis (MYRX), Ono Pharmaceutical (OPHLF) and Pivotal Therapeutics (PVTTF). View all competitors. Who are NeuroVive Pharmaceutical's key executives? NeuroVive Pharmaceutical's management team includes the following people: Mr. Erik Kinnmann M.D., Ph.D., M.B.A., Assoc. Prof., Chief Exec. Officer (Age 61)Ms. Catharina Jz Johansson, CFO & VP of Investor Relations (Age 52)Dr. Eskil Elmér, Chief Scientific Officer & VP of Discovery (Age 49)Daniel Schale, Director of CommunicationsDr. Magnus Hansson, Chief Medical Officer and VP of Preclinical & Clinical Devel. (Age 43) What is NeuroVive Pharmaceutical's stock symbol? NeuroVive Pharmaceutical trades on the OTCMKTS under the ticker symbol "NEVPF." How do I buy shares of NeuroVive Pharmaceutical? Shares of NEVPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is NeuroVive Pharmaceutical's stock price today? One share of NEVPF stock can currently be purchased for approximately $0.15. What is NeuroVive Pharmaceutical's official website? The official website for NeuroVive Pharmaceutical is www.neurovive.com. How can I contact NeuroVive Pharmaceutical? NeuroVive Pharmaceutical's mailing address is MEDICON VILLAGE SCHEELEVAGEN 2, LUND V7, 22381. The company can be reached via phone at 46-4-627-562-20 or via email at [email protected] This page was last updated on 6/1/2020 by MarketBeat.com Staff
